Keytruda melanoma treatment receives expanded indication

Merck yesterday announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA(R) (pembrolizumab), the company's anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first ["]